Day: April 30, 2021

The Annual General Meeting of Shareholders of Grigeo AB (hereinafter – the Company) was held on 30 April 2021. Due to the current situation with COVID-19 disease (coronavirus infection), it was possible to participate at the Company’s Annual General Meeting of Shareholders only in writing in advance by filling in the general ballot paper and submitting it to the Company. The Company’s Annual General Meeting of Shareholders adopted the following decisions: Assent to the Remuneration Report of the Company. To assent to the Company’s Remuneration Report, which is presented as a part of the Company’s consolidated annual report for the year 2020. Approval of consolidated and separate financial statements of the Company for the year ended 31 December 2020. To approve the consolidated and separate financial statements of the...

We hereby announce the audited annual information of Invalda INVL for the year 2020 approved at the shareholders’ meeting held on 30 April 2021. The person authorized to provide additional information is:Darius Sulnis, President of Invalda INVLE-mail Darius.Sulnis@invl.com  Attachment_Invalda INVL_Annual Information for 2020_

All business owners aspire to take the business to new heights. If you have dreams to expand to a new market, or launch a new product line, you are not alone. However, it is easier said than done. No matter the type of business you own or the industry you operate in, you can turn your aspirations into a reality with Hero FinCorp small business loans. The loans are designed to help your business and they have helped several businesses over the years. Hero FinCorp is a reliable institution in the country with a strong presence across the length and breadth of the country. They have helped several individuals turn their dreams into a reality. You can be a sole proprietor, partnership, or own a private or public corporation to be eligible for the loan. The biggest advantage of the loan is that you can use the funds for any purpose in the business....

PARIS and CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) — Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, informs its shareholders that the second combined Annual General Meeting (AGM) will be held on May 10, 2021 at 5PM CET, at Sorbonne University, 4 Place Jussieu – 75005 Paris, France. As a result of restrictions placed on the movement and gatherings of persons due to the COVID-19 pandemic, the Company’s Combined General Meeting will be held behind closed doors without the physical presence of its shareholders, in accordance...

AB Klaipėdos nafta (hereinafter – KN, the Company) announces the unaudited consolidated (hereinafter – the Group) and separate financial results for the three months ended 31 March 2021.Revenue for the 3 months of 2021 of the Group and the Company are EUR 15.7 million and EUR 15.0 million respectively and is lower by 21.5% and 24.2% compared to the same period of 2020 (EUR 20.0 million and EUR 19.8 million respectively). Net profit (loss) of the Group and the Company for the 3 months of 2021 amounts to EUR (9.1) million and EUR (9.2) million respectively and is EUR 8.7 million and EUR 8.9 million higher compared to the 3 months of 2020 (EUR (0.4) million and EUR (0.3) million respectively). Adjusted net profit (loss) of the Group and the Company for the 3 months of 2021 amounts to EUR 0.04 million and EUR (0.09) million respectively...

Sanoma Corporation, Stock Exchange Release, 30 April 2021 at 8:30 EETSanoma Corporation, Interim Report January–March 2021: Good start to the year driven by acquisitions and organic growth This release is a summary of Sanoma’s Interim Report January–March 2021. The complete report is attached to this release and is also available at sanoma.com/en/investors. Q1 2021                               The Group’s net sales grew to EUR 210 million (2020: 188) driven mainly by acquisitions both in Learning and Media Finland. The Group’s comparable net sales growth was 3% (2020: 2%). Operational EBIT excl. PPA declined to EUR -10 million (2020: -8). Earnings improved in Media Finland, and declined in Learning, which is typical for a growing learning company with seasonal losses of the first quarter increasing in-line with net sales. EBIT was...

CONSTI PLC INTERIM REPORT 30 APRIL 2021, at 8.30 a.m.                         Consti Plc Interim Report for January – March 2021 NET SALES AT PAR WITH PREVIOUS YEAR, ORDER INTAKE INCREASED 1–3/2021 highlights (comparison figures in parenthesis 1–3/2020):Net sales EUR 59.3 (59.0) million; growth 0.4% EBITDA EUR 0.9 (1.3) million and EBITDA margin 1.5% (2.2%) Operating result (EBIT) EUR 0.1 (0.5) million and EBIT margin 0.2% (0.8%) Order backlog EUR 196.5 (202.2) million; change -2.8% Order intake EUR 69.8 (62.1) million; growth 12.4% Free cash flow EUR -2.9 (2.0) million Earnings per share EUR -0.02 (0.01)                Guidance on the Group outlook for 2021: The Company estimates that its operating result for 2021 will be in the range of EUR 7-11 million. The range for 2021 profit guidance is wide due to the uncertainties related...

Press ReleaseNicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of NaproxcinodApril 30, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, today provided an update on Fera’s evaluation of naproxcinod for future development. Fera have been reviewing opportunities for the development of naproxcinod in a number of indications and have conducted pre-clinical development work on naproxcinod in models of both COVID-19 infections and sickle cell disease. Taking into consideration the data to date in the COVID-19 models and the environment for development of COVID-19 therapeutics, Fera has decided to no longer continue this route of evaluation. Efforts...

Leuven, BE, Boston, MA, US – April 30st, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies with a clinical stage portfolio in retinal vascular disorders. Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting which is held on May 1-7, 2021. Professor Alan Stitt, Ph.D., CSO at Oxurion NV comments: “We are happy to present these scientific findings at the ARVO 2021 annual meeting. A deep understanding of the cellular and molecular mechanisms that underpin retinal disease and the use relevant preclinical models are instrumental for developing novel therapeutics.  We are happy to share our insights with the global vision research community...